Literature DB >> 26605306

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

Yuankai Shi1, Yan Sun1, Cuimin Ding1, Ziping Wang1, Changli Wang1, Zheng Wang1, Chong Bai1, Chunxue Bai1, Jifeng Feng1, Xiaoqing Liu1, Fang Li1, Yue Yang1, Yongqian Shu1, Milu Wu1, Jianxing He1, Yiping Zhang1, Shucai Zhang1, Gongyan Chen1, Honghe Luo1, Rongcheng Luo1, Caicun Zhou1, Yanbin Zhou1, Qingsong Pang1, Hong Zhao1, Qiong Zhao1, Aiqin Gu1, Yang Ling1, Cheng Huang1, Baohui Han1, Shunchang Jiao1, Hong Jiao1.   

Abstract

Entities:  

Year:  2015        PMID： 26605306      PMCID： PMC4630551          DOI： 10.3978/j.issn.2305-5839.2015.10.30

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Authors:  Yi-Long Wu; Wen-Zhao Zhong; Long-Yun Li; Xiao-Tong Zhang; Li Zhang; Cai-Cun Zhou; Wei Liu; Bin Jiang; Xin-Lin Mu; Jia-Ying Lin; Qing Zhou; Chong-Rui Xu; Zhen Wang; Guo-Chun Zhang; Tony Mok
Journal:  J Thorac Oncol       Date:  2007-05       Impact factor: 15.609

3.  A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).

Authors:  Xingsheng Hu; Baohui Han; Aiqin Gu; Yiping Zhang; Shun Chang Jiao; Chang-Li Wang; Jintao He; Xueke Jia; Li Zhang; Jiewen Peng; Meina Wu; Kejing Ying; Junye Wang; Kewei Ma; Shucai Zhang; Changxuan You; Fenlai Tan; Yinxiang Wang; Lieming Ding; Yan Sun
Journal:  Lung Cancer       Date:  2014-09-16       Impact factor: 5.705

4.  [The diagnosis and treatment guideline of Chinese patients with EGFR gene active mutation and ALK fusion gene-positive non-small cell lung cancer (2014 version)].

Authors: 
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2014-07

5.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

6.  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Authors:  Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shujun Yang; Xiaoqing Liu; Yunpeng Liu; Shun Lu; Jie Wang; Shucai Zhang; Caicun Zhou; Xiangwei Zhang; Nobuya Hayashi; Mengzhao Wang
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316

7.  Annual report on status of cancer in China, 2011.

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Jie He
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

8.  [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].

Authors:  Xi Li; Xin-jie Yang; Yi-fen Sun; Na Qin; Jia-lin Lü; Yu-hua Wu; Hui Zhang; Quan Zhang; Shu-cai Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-08

9.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

10.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321
View more
  8 in total

1.  The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer.

Authors:  Long Wang; Tiantian Shi; Li Feng; Zhisong Fan; Xiaoli Xu; Xinliang Zhou; Xue Zhang; Jing Han; Li Jing; Jiayin Liu; Yujie Shan; Fengling Liu; Jing Zuo; Yudong Wang
Journal:  Cancer Manag Res       Date:  2021-03-18       Impact factor: 3.989

Review 2.  The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.

Authors:  Antonia Högnäsbacka; Alex J Poot; Danielle J Vugts; Guus A M S van Dongen; Albert D Windhorst
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-05

3.  The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China.

Authors:  Qiang Shi; Shanlian Hu; Wesley E Furnback; Gregory F Guzauskas; Jiejing Shen; Bruce Cm Wang
Journal:  Clinicoecon Outcomes Res       Date:  2017-02-03

4.  Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program.

Authors:  Hai-Yan Tu; Yi-Long Wu
Journal:  Onco Targets Ther       Date:  2020-12-07       Impact factor: 4.147

Review 5.  Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.

Authors:  Gabriele Hintzen; Holger J Dulat; Erich Rajkovic
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

6.  A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).

Authors:  Qing Zhou; Yong Song; Xin Zhang; Gong-Yan Chen; Dian-Sheng Zhong; Zhuang Yu; Ping Yu; Yi-Ping Zhang; Jian-Hua Chen; Yi Hu; Guo-Sheng Feng; Xia Song; Qiang Shi; Lu Lu Yang; Ping Hai Zhang; Yi-Long Wu
Journal:  BMC Cancer       Date:  2017-07-03       Impact factor: 4.430

Review 7.  EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Cancer Res       Date:  2019-01       Impact factor: 1.241

8.  Analysis of circular RNA expression profiles of lung cancer in Xuanwei, China.

Authors:  Yan Wang; Ling-Jiao Lu; Yong Duan; Xiao Liu; Yue Mao; Yu Chen; Yan-Liang Zhang
Journal:  J Clin Lab Anal       Date:  2020-08-26       Impact factor: 3.124
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.